Cargando…
The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
Pharmaceutical agonists of peroxisome proliferator-activated receptors (PPARs) are widely used in the management of type 2 diabetes, chiefly as lipid-lowering agents and oral hypoglycaemic agents. Although most of the focus has been placed on their cardiovascular effects, both positive and negative,...
Autores principales: | Thomas, M. C., Jandeleit-Dahm, K. A., Tikellis, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289856/ https://www.ncbi.nlm.nih.gov/pubmed/22448165 http://dx.doi.org/10.1155/2012/456529 |
Ejemplares similares
-
Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats
por: Afzal, Sheryar, et al.
Publicado: (2020) -
The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021) -
Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008) -
Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013) -
Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)